Filing Details CX Institutional, a registered investment adviser, reduced its position in AbbVie Inc. (NYSE:ABBV) during Q2 2026, according to its most recent 13F filing with the…
CX Institutional, a registered investment adviser, reduced its position in AbbVie Inc. (NYSE:ABBV) during Q2 2026, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm sold 11,667 shares of the Healthcare company, reducing its total holdings to 78,286 shares valued at approximately $19.7M as of the filing date. This represents a 13.0% decrease in the position.
AbbVie Inc.'s stock currently trades at $254.57 with a market capitalization of $410.1B.
Institutional selling doesn't always signal a bearish outlook. Large funds regularly trim positions for portfolio rebalancing, client redemptions, or to lock in gains. That said, when a major holder like CX Institutional reduces exposure to AbbVie Inc., it's worth monitoring whether other institutions are making similar moves.
Healthcare stocks have attracted institutional attention as an aging population drives long-term demand. AbbVie Inc. operates in a sector where regulatory developments and pipeline progress can significantly impact institutional positioning.
Investors should note that 13F filings reflect holdings as of the end of the reporting quarter and are filed up to 45 days later. The position may have changed since the filing date. 13F data is most useful when analyzed alongside other signals such as insider transactions, analyst ratings, and fundamental trends.
Related Tools: Insider Trades Tracker | View ABBV Stock Page
A 13F filing is a quarterly SEC report required for institutional managers with over $100 million in assets. It discloses equity holdings, providing transparency into how firms like CX Institutional position their portfolios.
View all institutional holders on our ABBV institutional ownership page.
Current market data
NYSE · ABBV
$263.04
Up: +$1.24 · +0.47%
Live quote updated
Keep reading
